Based on these suspected opposing effects of low BRCA1 expression on outcomes in BC and CRC, we investigated the value of BRCA1 mRNA-low versus -high expression as a prognostic biomarker in these cancers and further investigated differences in age, sex, tumor stage, metastasis score, tumor size and subtype, and race across these patient cohorts. The gene discussed is BRCA1; the disease is cancer.